Cargando…

K-ras mutations and HLA-DR expression in large bowel adenomas.

A total of 72 sporadic colorectal adenomas in 56 patients were studied for the presence of point mutations in codons 12 and 13 of the K-ras gene and for HLA-DR antigen expression related to clinicopathological variables. Forty K-ras mutations in 39 adenomas were found (54%): 31 (77%) in codon 12 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Norheim Andersen, S., Breivik, J., Løvig, T., Meling, G. I., Gaudernack, G., Clausen, O. P., Schjölberg, A., Fausa, O., Langmark, F., Lund, E., Rognum, T. O.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074621/
https://www.ncbi.nlm.nih.gov/pubmed/8679466
_version_ 1782138005894463488
author Norheim Andersen, S.
Breivik, J.
Løvig, T.
Meling, G. I.
Gaudernack, G.
Clausen, O. P.
Schjölberg, A.
Fausa, O.
Langmark, F.
Lund, E.
Rognum, T. O.
author_facet Norheim Andersen, S.
Breivik, J.
Løvig, T.
Meling, G. I.
Gaudernack, G.
Clausen, O. P.
Schjölberg, A.
Fausa, O.
Langmark, F.
Lund, E.
Rognum, T. O.
author_sort Norheim Andersen, S.
collection PubMed
description A total of 72 sporadic colorectal adenomas in 56 patients were studied for the presence of point mutations in codons 12 and 13 of the K-ras gene and for HLA-DR antigen expression related to clinicopathological variables. Forty K-ras mutations in 39 adenomas were found (54%): 31 (77%) in codon 12 and nine (23%) in codon 13. There was a strong relationship between the incidence of K-ras mutations and adenoma type, degree of dysplasia and sex. The highest frequency of K-ras mutations was seen in large adenomas of the villous type with high-grade dysplasia. Fourteen out of 15 adenomas obtained from 14 women above 65 years of age carried mutations. HLA-DR positivity was found in 38% of the adenomas, large tumours and those with high-grade dysplasia having the strongest staining. Coexpression of K-ras mutations and HLA-DR was found significantly more frequently in large and highly dysplastic adenomas, although two-way analysis of variance showing size and grade of dysplasia to be the most important variable. None of the adenomas with low-grade dysplasia showed both K-ras mutation and HLA-DR positivity (P = 0.004). K-ras mutation is recognised as an early event in colorectal carcinogenesis. The mutation might give rise to peptides that may be presented on the tumour cell surface by class II molecules, and thereby induce immune responses against neoplastic cells. IMAGES:
format Text
id pubmed-2074621
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20746212009-09-10 K-ras mutations and HLA-DR expression in large bowel adenomas. Norheim Andersen, S. Breivik, J. Løvig, T. Meling, G. I. Gaudernack, G. Clausen, O. P. Schjölberg, A. Fausa, O. Langmark, F. Lund, E. Rognum, T. O. Br J Cancer Research Article A total of 72 sporadic colorectal adenomas in 56 patients were studied for the presence of point mutations in codons 12 and 13 of the K-ras gene and for HLA-DR antigen expression related to clinicopathological variables. Forty K-ras mutations in 39 adenomas were found (54%): 31 (77%) in codon 12 and nine (23%) in codon 13. There was a strong relationship between the incidence of K-ras mutations and adenoma type, degree of dysplasia and sex. The highest frequency of K-ras mutations was seen in large adenomas of the villous type with high-grade dysplasia. Fourteen out of 15 adenomas obtained from 14 women above 65 years of age carried mutations. HLA-DR positivity was found in 38% of the adenomas, large tumours and those with high-grade dysplasia having the strongest staining. Coexpression of K-ras mutations and HLA-DR was found significantly more frequently in large and highly dysplastic adenomas, although two-way analysis of variance showing size and grade of dysplasia to be the most important variable. None of the adenomas with low-grade dysplasia showed both K-ras mutation and HLA-DR positivity (P = 0.004). K-ras mutation is recognised as an early event in colorectal carcinogenesis. The mutation might give rise to peptides that may be presented on the tumour cell surface by class II molecules, and thereby induce immune responses against neoplastic cells. IMAGES: Nature Publishing Group 1996-07 /pmc/articles/PMC2074621/ /pubmed/8679466 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Norheim Andersen, S.
Breivik, J.
Løvig, T.
Meling, G. I.
Gaudernack, G.
Clausen, O. P.
Schjölberg, A.
Fausa, O.
Langmark, F.
Lund, E.
Rognum, T. O.
K-ras mutations and HLA-DR expression in large bowel adenomas.
title K-ras mutations and HLA-DR expression in large bowel adenomas.
title_full K-ras mutations and HLA-DR expression in large bowel adenomas.
title_fullStr K-ras mutations and HLA-DR expression in large bowel adenomas.
title_full_unstemmed K-ras mutations and HLA-DR expression in large bowel adenomas.
title_short K-ras mutations and HLA-DR expression in large bowel adenomas.
title_sort k-ras mutations and hla-dr expression in large bowel adenomas.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074621/
https://www.ncbi.nlm.nih.gov/pubmed/8679466
work_keys_str_mv AT norheimandersens krasmutationsandhladrexpressioninlargeboweladenomas
AT breivikj krasmutationsandhladrexpressioninlargeboweladenomas
AT løvigt krasmutationsandhladrexpressioninlargeboweladenomas
AT melinggi krasmutationsandhladrexpressioninlargeboweladenomas
AT gaudernackg krasmutationsandhladrexpressioninlargeboweladenomas
AT clausenop krasmutationsandhladrexpressioninlargeboweladenomas
AT schjolberga krasmutationsandhladrexpressioninlargeboweladenomas
AT fausao krasmutationsandhladrexpressioninlargeboweladenomas
AT langmarkf krasmutationsandhladrexpressioninlargeboweladenomas
AT lunde krasmutationsandhladrexpressioninlargeboweladenomas
AT rognumto krasmutationsandhladrexpressioninlargeboweladenomas